The chimeric antigen receptor (CAR) is an artificial T cell surface receptor that simulates the physiological functions of the native T cell receptor (TCR). With gene transfer technologies, T cells can be genetically modified to stably express CAR on their surface. The CAR-T cells have a combined advantage of antibody tumor specificity and T cells' effector function. Today the clinical trials with leukemia,lymphoma and melanoma have seen impressive results, but the clinical use of CAR-T cells for solid tumors has faced some challenges due to certain characteristics of solid tumors. In the future the third generation CAR-T cells, dual-specificity CAR-T cells and some new discoveries will pave a way for the application of CAR-T cells for solid tumors. In this paper, we reviewed the application of CAR-T cells for treatment of solid tumors in recent years.